ID
25293
Description
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease
Keywords
Versions (2)
- 8/31/17 8/31/17 -
- 9/4/17 9/4/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 31, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Patient's Daily Diary determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
Patient's Daily Diary determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
Description
HEALTH RELATED EVENTS
Alias
- UMLS CUI-1
- C1562065
Description
event
Data type
text
Alias
- UMLS CUI [1]
- C0441471
Description
start date and time
Data type
datetime
Alias
- UMLS CUI [1]
- C0808070
- UMLS CUI [2]
- C1301880
Description
stop date and time
Data type
datetime
Alias
- UMLS CUI [1]
- C0806020
- UMLS CUI [2]
- C1522314
Description
Only tick the box, if the event is still going on.
Data type
text
Alias
- UMLS CUI [1]
- C0549178
Similar models
Patient's Daily Diary determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
C0376660 (UMLS CUI [1,2])
C1522634 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2])
C1522314 (UMLS CUI [2])